Elicio Therapeutics is a clinical-stage biotech company developing targeted immunotherapies, especially cancer vaccines, using its proprietary Amphiphile platform to generate strong T cell responses.

# Elicio Therapeutics Company Summary

## Overview
- **Type:** Clinical-stage biotechnology company
- **Focus:** Development of immunotherapies, especially cancer immunotherapies
- **Technology:** Proprietary Amphiphile (“AMP”) platform designed for targeted delivery of immunotherapeutic payloads to lymph nodes to generate strong T cell responses

## Core Strategy
- Develop lymph node-targeted immunotherapies to mobilize immune responses against cancer
- Focus on off-the-shelf cancer vaccines targeting well-characterized neoantigens derived from validated tumor mutations (e.g., KRAS, BRAF, TP53)
- Aim to treat cancers with high unmet needs, like KRAS-mutated solid tumors, via therapeutic vaccines
- Expand platform applications to infectious disease, autoimmune diseases, and cell therapies (e.g., CAR-T, TCR-T)

## Lead Programs & Product Candidates
- **ELI-002:** A cancer vaccine targeting mutated KRAS, currently in Phase 2 trials for pancreatic ductal adenocarcinoma (PDAC). It is designed to evoke T cell responses against KRAS mutations, which are present in about 25% of all solid tumors including PDAC, CRC, and NSCLC.
- **ELI-007:** Preclinical program targeting mutated BRAF, used in melanoma and other cancers.
- **ELI-008:** Preclinical program targeting mutant TP53, relevant in multiple cancer types.

## Clinical Development Milestones
- Completed enrollment in Phase 1 for ELI-002 (2-peptide and 7-peptide formulations)
- Phase 2 trial for ELI-002 in pancreatic cancer (AMPLIFY-7P) with enrollment completed, interim analysis expected in Q3 2025
- Early promising results: high T cell response rates, tumor biomarker reductions, and relapse-free survival statistics in Phase 1 studies

## Employees & Size
- **Total Employees:** 32 (as of December 31, 2024)
- **Employees engaged in R&D and manufacturing:** 26
- **Employees with advanced degrees:** 10 (including Ph.D. or M.D.)

## Financials (2024)
- **Revenue:** None (the company has not yet commercialized any products)
- **Net Loss for 2024:** $51.9 million
- **Loss for 2023:** $35.2 million
- **Research & Development Expenses (2024):** $33.7 million
- **Cash runway:** Estimated to fund operations into Q4 2025
- **Market Capitalization (as of June 28, 2024):** Approximately $33.2 million
- **Shares Outstanding (as of March 25, 2025):** 15,953,524

## Additional Details
- **Intellectual Property:** Holds several patents related to AMP platform, neoantigen targets, and antibody conjugates; licensed from MIT and other universities
- **Manufacturing:** Outsourced to third-party contract manufacturing organizations (CMOs)
- **Traction:** Completed enrollment for key clinical trials with promising early data, but no drugs are yet approved or generating revenue
- **Regulatory Status:** The company's products are in clinical and preclinical stages; no approved therapies yet

## Summary
Elicio Therapeutics is focused on creating lymph node-targeted cancer vaccines leveraging its proprietary AMP platform, with several pipeline candidates in clinical and preclinical stages. The company has not yet generated revenue, incurred significant losses, and its operational existence depends on continued funding. It has a small team of 32 employees and expects to fund operations through Q4 2025.

Elicio Therapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for treating cancer and infectious diseases using its proprietary Amphiphile technology platform.

# Elicio Therapeutics, Inc. Overview

Elicio Therapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for treating cancer and infectious diseases. The company leverages its proprietary Amphiphile technology platform to create a new class of therapeutics that aim to enhance immune responses against tumors and infectious threats.

## Business Model and Focus

Elicio Therapeutics' primary business activities include:

- **Product Development**: The company is engaged in the development of therapeutic candidates, particularly ELI-002, a therapy designed to enhance anti-tumor immune responses through its innovative Amphiphile platform.
- **Clinical Trials**: Elicio conducts clinical trials to demonstrate the safety and efficacy of its product candidates, aiming to bring new treatments to market for unmet medical needs in oncology and infectious diseases.

### Key Product Candidates
- **ELI-002**: An investigational product designed to treat cancer by stimulating the immune system and is currently undergoing clinical trials. The aim is to provide a promising treatment option for patients with difficult-to-treat tumors.

### Research and Development
The company's R&D efforts focus on both preclinical and clinical stages of product development, with a significant emphasis on immuno-oncology.

## Financial Information (as of December 31, 2023)
- **Employees**: Elicio Therapeutics employs approximately 25 people, including a team of experienced professionals in scientific, clinical, and operational roles.
- **Revenue**: Elicio is still in the clinical stages of development and as such, does not yet generate significant revenue.
- **Funding**: The company has raised capital through equity offerings to support its research and development activities. Notably:
  - In December 2023, Elicio raised approximately $7.0 million through a subscription agreement with GKCC, LLC.
  - In March 2024, Elicio raised approximately $6.0 million from the sale of pre-funded warrants.

## Customer Base
As a clinical-stage biotechnology company, Elicio does not have a traditional customer base but aims to serve patients suffering from cancer and infectious diseases, along with healthcare providers and institutions upon commercialization of its products.

## Market Position
Elicio operates within a competitive landscape that includes various biotechnology firms advancing immunotherapy. The company's unique Amphiphile platform positions it for potential breakthroughs in immunotherapeutics.

## Conclusion
Elicio Therapeutics, Inc. is dedicated to advancing innovative cancer and infectious disease therapies. As it progresses towards commercializing its drug candidates, it aims to significantly impact patient care in the therapeutic landscape of oncology and infectious diseases.

Elicio Therapeutics, Inc.

10-K / March 31, 2025

10-K / April 29, 2024

10-K / March 31, 2025

Elicio Therapeutics Company Summary

Overview

Core Strategy

Lead Programs & Product Candidates

Clinical Development Milestones

Employees & Size

Financials (2024)

Additional Details

Summary